Kratom and Pregnancy: What You Need to Know About Safety and Risks

What the Research Says About Kratom and Pregnancy

Research on kratom use during pregnancy is limited but consistently raises serious concerns. As of 2026, the available wellness literature consists primarily of case reports and systematic reviews — no large-scale controlled studies have been conducted on kratom’s effects during pregnancy.

A 2021 systematic review published in the Journal of Perinatology (Wright et al.) analyzed six case reports of prenatal kratom exposure. In every case, both the mother and infant experienced transitioning challenges that required pharmacological management. The infants developed neonatal abstinence syndrome (NAS), a condition typically associated with traditional substance exposure during pregnancy.

A 2023 literature review published in Research and Reports in Neonatology (Tandfonline) identified 12 unique articles documenting kratom exposure during pregnancy. The findings were consistent: the majority of exposed infants developed NAS, and more than half required management with morphine.

Why Research Is Limited

• Kratom is unregulated — product strength and purity vary widely, making standardized studies difficult
• No standard drug test detects kratom — mitragynine requires specialized liquid chromatography–mass spectrometry, meaning many cases likely go undetected
• Self-reporting barriers — pregnant women may not disclose kratom use to healthcare providers due to stigma or not recognizing it as a substance of concern
• Ethical constraints — researchers cannot ethically administer kratom to pregnant participants, limiting data to observational case reports

How Kratom May Affect Pregnancy

Kratom contains over 40 alkaloids, but two are primarily responsible for its pharmacological effects: mitragynine and 7-hydroxymitragynine. Both act on alkaloid receptors in the brain, which is why kratom produces effects similar to traditional substances — and why it carries similar risks during pregnancy.

Placental Transfer

Kratom’s active alkaloids are small enough to cross the placental barrier, meaning the developing fetus is exposed to the same traditional substance-like compounds as the mother. 7-hydroxymitragynine has been reported to have higher potency than morphine at alkaloid receptors, despite being present in smaller quantities in the plant.

Potential Risks to the Mother

Potential Risks to the Fetus and Newborn

Neonatal Abstinence Syndrome (NAS) and Kratom

Neonatal abstinence syndrome occurs when a newborn withdraws from substances they were exposed to in the womb. Because kratom activates alkaloid receptors, NAS from kratom exposure closely resembles NAS from traditional traditional substance exposure.

NAS Symptoms in Kratom-Exposed Newborns

Based on published case reports, kratom-exposed infants have shown:

• Irritability and excessive crying — often inconsolable, high-pitched cry
• Tremors and jitteriness — involuntary shaking or muscle twitching
• Poor feeding — difficulty latching, weak or uncoordinated sucking
• Gastrointestinal distress — vomiting, diarrhea, poor weight gain
• Sleep disturbances — difficulty settling, short sleep cycles
• Increased muscle tone — stiffness, hyperactive reflexes
• Seizures — in severe cases, particularly with high-dose maternal use
• Nasal congestion and sneezing — common transitioning from traditional options signs in newborns

Typical NAS Timeline for Kratom Exposure

• Birth to 24 Hours
  Initial symptoms may appear within hours of delivery. Healthcare providers use scoring tools (like the Finnegan Scale) to assess habit-breaking periods severity.
• 24–72 Hours
  Symptoms typically peak during this window. Scoring determines whether pharmacological management is needed.
• 1–2 Weeks
  Active habit-breaking periods period. Infants requiring morphine management are closely monitored with gradual dose reduction.
• 2–8 Weeks
  Resolution phase. Some case reports document morphine management lasting approximately 2 months for kratom-exposed infants.

Kratom and Breastfeeding

There is virtually no research on whether kratom alkaloids transfer into breast milk or what effects they may have on a nursing infant. However, given what we know about kratom’s pharmacology, most healthcare professionals advise against kratom use while breastfeeding.

Why Caution Is Warranted

• Traditional substance-like compounds commonly transfer into breast milk — kratom’s alkaloids share pharmacological properties with known traditional substances
• Infant metabolism is immature — newborns process substances more slowly than adults, increasing the risk of accumulation
• No safe dosage established — without research, there is no way to determine a “safe” amount of kratom exposure through breast milk
• Potential sedation — traditional substance agonists in breast milk could cause excessive drowsiness, breathing difficulties, or feeding problems in nursing infants

If You Are Currently Using Kratom and Are Pregnant

Recommended Steps

1. Disclose kratom use to your OB-GYN or midwife — your provider needs complete information to ensure safe prenatal care. Kratom will not appear on standard drug tests, so verbal disclosure is essential.
2. Request a supervised tapering plan — your doctor can help you reduce kratom use gradually to minimize habit-breaking periods risks for both you and your baby.
3. Discuss medication-assisted management (MAT) — buprenorphine has been used in some case reports to manage kratom dependence during pregnancy, with established safety profiles for prenatal use.
4. Attend all prenatal appointments — regular monitoring allows your healthcare team to track fetal development and prepare for any complications.
5. Prepare for NAS monitoring — your delivery team should be informed of kratom exposure so the newborn can be monitored and managed if NAS symptoms develop.

Safer Alternatives During Pregnancy

Many people use kratom for physical relief, tension management, or mood support — all common concerns during pregnancy. Here are evidence-based alternatives to discuss with your healthcare provider: